SPYRE THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
SPYRE THERAPEUTICS, INC. (SYRE) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-11-07
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-06-30 was 101.65K shares, a 90.85% decline year-over-year.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 250.00K shares, a 78.37% decline year-over-year.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-09-30 was 278.15K shares.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 695.11K shares, a 34.64% decline from fiscal 2022.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 1.06M shares, a 58.07% increase from fiscal 2021.
- SPYRE THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 672.85K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-07 | 116.79K shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 101.65K shares 10-Q · filed 2024-08-07 | 175.82K shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 250.00K shares 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 695.11K shares 10-K · filed 2024-02-29 | |||
| 2023-09-30 | 278.15K shares 10-Q · filed 2024-11-07 | 845.11K shares 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 1.11M shares 10-Q · filed 2024-08-07 | 1.13M shares 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 1.16M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 1.06M shares 10-K · filed 2024-02-29 | |||
| 2021-12-31 | 672.85K shares 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |